# ClinicalIntelPulse Trial Brief

> ClinicalIntelPulse Trial Brief is a paid API for AI agents from clinicalintelpulse.theaslangroupllc.com, paid per call via x402, $0.1/call, status unknown (last checked 2026-09-15).

Retrieves a comprehensive deep-dive profile of a specific ClinicalTrials.gov study by NCT ID, including trial design, endpoints, enrollment, sponsor, and publications.

## Facts

- Endpoint: GET https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief
- Price: $0.1/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-15
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-trial-brief-a0256c9e
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_Yj5qpaEnkbqHw6pscBrMt

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-trial-brief-a0256c9e
```

Example prompt: Pull the full trial brief for NCT04280705 — I need the trial design, primary and secondary endpoints, enrollment status, recruiting countries, sponsor, and any published outcomes.

## When to prefer this

Use this endpoint when you need a deep, structured profile of a single known clinical trial and already have its NCT ID. It is ideal for research agents, biotech analysts, and competitive intelligence workflows that need granular trial-level data including endpoints, recruitment details, and publications — rather than a broad disease-level landscape view.

## Known failure modes

- Invalid or malformed NCT ID returns a 400 or not-found error
- NCT ID not yet indexed in ClinicalTrials.gov returns empty or null result
- Trial record has minimal data (e.g. newly registered study) resulting in sparse output
- Payment authorization failure via x402 protocol returns 402
- Rate limiting or upstream ClinicalTrials.gov API downtime causes timeout

## How this service works

Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents.

## Output

A structured profile of the clinical trial including: trial design and phase, primary and secondary endpoints, current enrollment status and target enrollment numbers, list of participating countries, sponsor and collaborator names, inclusion/exclusion recruitment criteria, outcome measures, and linked publications.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "nct_id": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "design": {
   "arms": [
    "Tiragolumab + Atezolizumab + Carboplatin/Paclitaxel",
    "Placebo + Atezolizumab + Carboplatin/Paclitaxel"
   ],
   "masking": "Double-Blind",
   "allocation": "Randomized",
   "study_type": "INTERVENTIONAL",
   "primary_purpose": "Treatment"
  },
  "endpoints": {
   "primary": [
    "Progression-Free Survival (PFS)",
    "Overall Survival (OS)"
   ],
   "secondary": [
    "Objective Response Rate",
    "Duration of Response",
    "Safety/Tolerability"
   ]
  },
  "enrollment": {
   "actual": 534,
   "planned": 534,
   "countries": [
    "United States",
    "Spain",
    "Germany",
    "Japan",
    "Australia"
   ]
  },
  "interventions": [
   {
    "name": "Tiragolumab",
    "role": "Anti-TIGIT immune checkpoint inhibitor",
    "type": "DRUG"
   }
  ],
  "query_summary": {
   "nct_id": "NCT04368728",
   "retrieved_from": "ClinicalTrials.gov v2 API"
  },
  "trial_identity": {
   "phase": "PHASE3",
   "title": "A Study of Tiragolumab in Combination With Atezolizumab and Chemotherapy Versus Placebo in Untreated Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01)",
   "status": "COMPLETED",
   "sponsor": "Hoffmann-La Roche",
   "start_date": "2019-06",
   "primary_completion": "2022-12"
  },
  "outcome_summary": "SKYSCRAPER-01 failed to meet primary PFS endpoint (HR 0.93). Significant negative readout for anti-TIGIT in NSCLC.",
  "regulatory_implications": "Setback for Roche tiragolumab program. Broader TIGIT class facing headwinds."
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-trial-brief-a0256c9e/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.theaslangroupllc.com](https://www.zero.xyz/host/clinicalintelpulse.theaslangroupllc.com/llms.txt)